Recombinant Human IL-17A/F
Non-reducing (-) and reducing (+) conditions in a 4 - 20% Tris-Glycine gel stained with Coomassie Blue. 1 μg of protein was loaded in each lane. Human IL-17A/F is a heterodimer and has a predicted Mw of 30.7 kDa.
Achieve Purchasing Synergy
Request a quote at [email protected] for 2 or more vials of any Growth Factor to receive a discount. Discounts range from 5 to 20% according to the size of your order.
PODS® Growth Factors
The product is currently not available as PODS®, please check back in the future.Description
Interleukin-17A/F (IL-17A/F) is a heterodimer that is composed of the interleukin-17A (IL-17A) and interleukin-17F (IL-17F) members of the IL-17 family of cytokines. IL-17A/F is produced by T helper 17 cells (Th17) following interleukin-23 (IL-23) stimulation. IL-17A/F signals through the IL-17RA/IL-17RC receptor complex and functions to regulate inflammatory responses. IL-17A/F induces chemokine and airway neutrophilia production, similar in function to IL-17A and IL-17F homodimers. In regard to these functions, IL-17A/F is less active than the IL-17A homodimer and shows greater activity than the IL-17F homodimer. Human and rat IL-17A/F are active on mouse cells.Activity Assay
Human IL-17A/F is fully biologically active when compared to standard. The activity is determined by the ability to produce mouse IL-3 by 3T3 cells and it is typically less than 50 ng/ml. This corresponds to an expected specific activity of 2.0 x 104 units/mg.AA Sequence
MIVKAGITIP RNPGCPNSED KNFPRTVMVN LNIHNRNTNT NPKRSSDYYN RSTSPWNLHR NEDPERYPSV IWEAKCRHLG CINADGNVDY HMNSVPIQQE ILVLRREPPH CPNSFRLEKI LVSVGCTCVT PIVHHVAAlternative Names
Interleukin-17A, interleukin 17A, IL17A, IL 17A| Product Details | |
|---|---|
| Length | 137 / 274 aa |
| Molecular Weight | 15.7 / 31.3 kDa |
| Structure | Monomer |
| Source | E. coli |
| Accession Number | Q16552 |
| Purity | ≥95% determined by reducing and non-reducing SDS-PAGE |
| Endotoxin Level | ≤1.00 EU/μg as measured by kinetic LAL |
| Formulation | Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA) |
| Reconstitution | Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile 10 mM HCI at 0.1 mg/ml, which can be further diluted into other aqueous solutions. |
| Stability and Storage |
12 months from date of receipt when stored at -20°C to -80°C as supplied. 1 month when stored at 4°C after reconstituting as directed. 3 months when stored at -20°C to -80°C after reconstituting as directed. |
